Ergomed PLC (ERGO) Earns “Buy” Rating from Numis Securities Ltd

Numis Securities Ltd reiterated their buy rating on shares of Ergomed PLC (LON:ERGO) in a research note issued to investors on Friday. The firm currently has a GBX 280 ($3.68) price target on the stock.

Ergomed PLC (LON ERGO) opened at 181.00 on Friday. The company’s market cap is GBX 73.37 million. The company’s 50 day moving average price is GBX 176.94 and its 200-day moving average price is GBX 191.68. Ergomed PLC has a one year low of GBX 118.00 and a one year high of GBX 216.88.

Ergomed PLC (LON:ERGO) last released its quarterly earnings results on Monday, September 18th. The company reported GBX 1.20 ($0.02) earnings per share (EPS) for the quarter. Ergomed PLC had a return on equity of 2.69% and a net margin of 2.07%. The firm had revenue of GBX 2,291 million for the quarter. On average, analysts forecast that Ergomed PLC will post $7.80 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/10/ergomed-plc-ergo-earns-buy-rating-from-numis-securities-ltd.html.

Ergomed PLC Company Profile

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research serv

Ergomed PLC (LON ERGO) opened at 181.00 on Friday. The company’s market cap is GBX 73.37 million. The company’s 50 day moving average price is GBX 176.94 and its 200-day moving average price is GBX 191.68. Ergomed PLC has a one year low of GBX 118.00 and a one year high of GBX 216.88.

Ergomed PLC (LON:ERGO) last released its quarterly earnings results on Monday, September 18th. The company reported GBX 1.20 ($0.02) earnings per share (EPS) for the quarter. Ergomed PLC had a return on equity of 2.69% and a net margin of 2.07%. The firm had revenue of GBX 2,291 million for the quarter. On average, analysts forecast that Ergomed PLC will post $7.80 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/10/ergomed-plc-ergo-earns-buy-rating-from-numis-securities-ltd.html.

Ergomed PLC Company Profile

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply